within Pharmacolibrary.Drugs.ATC.C;

model C07AA19
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 20.0,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.0013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Bupranolol is a non-selective beta-adrenergic antagonist (beta-blocker). It was previously used in the management of hypertension, angina pectoris, and certain cardiac arrhythmias. Due to its very short half-life, it has largely fallen out of clinical use and has been superseded by longer-acting agents. Bupranolol is not widely approved or in clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult male volunteers after oral administration.</p><h4>References</h4><ol><li>A Prakash, A Markham,Long-acting isosorbide mononitrate.,Drugs,1999<a href='https://pubmed.ncbi.nlm.nih.gov/9951954/'>https://pubmed.ncbi.nlm.nih.gov/9951954/</a></li><li>J Kemken, A Ziegler, B W MÃ¼ller,Influence of supersaturation on the pharmacodynamic effect of bupranolol after dermal administration using microemulsions as vehicle.,Pharmaceutical research,1992<a href='https://pubmed.ncbi.nlm.nih.gov/1495902/'>https://pubmed.ncbi.nlm.nih.gov/1495902/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C07AA19;
